Austin, Texas, United States, August 3rd, 2026, FinanceWireRegentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to es…
Austin, Texas, United States, July 30th, 2026, FinanceWireRegentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee ost…
Austin, Texas, United States, July 29th, 2026, FinanceWireCartilage Regeneration Gains Strategic ValidationThe orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained…
Austin, Texas, United States, July 27th, 2026, FinanceWireRegentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundr…
Austin, Texas, United States, July 15th, 2026, FinanceWireRegentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s pl…
